Impact of zoledronate on FMAU positron emission tomography (PET) scanning results in metastatic prostate cancer.

Omid S. Tehrani,Ulka N. Vaishampayan,Jawana M. Lawhorn-Crews,Lance K. Heilbrun,Kimberlee Dobson,Daryn Smith,Brenda Dickow,Anthony F. Shields

Impact of zoledronate on FMAU positron emission tomography (PET) scanning results in metastatic prostate cancer.

2015

Omid S. Tehrani
Ulka N. Vaishampayan
Jawana M. Lawhorn-Crews
Lance K. Heilbrun
Kimberlee Dobson
Daryn Smith
Brenda Dickow
Anthony F. Shields

e16069 Background: We conducted a pilot trial utilizing a [18F]FMAU [(1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)thymine] PET as a tumor tracer to evaluate its reproducibility and changes in maximu...

Keywords:

Pathology
Nuclear medicine
Positron emission tomography
Prostate cancer
Medicine
pilot trial
Reproducibility

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations